Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $11.9 million.

  • Heron Therapeutics' Cash from Investing Activities rose 19869.02% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 223525.97%. This contributed to the annual value of $18.7 million for FY2024, which is 399.56% up from last year.
  • Per Heron Therapeutics' latest filing, its Cash from Investing Activities stood at $11.9 million for Q3 2025, which was up 19869.02% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Cash from Investing Activities peaked at $39.7 million during Q2 2021, and registered a low of -$36.0 million during Q3 2022.
  • Its 5-year average for Cash from Investing Activities is $4.6 million, with a median of $4.0 million in 2024.
  • Per our database at Business Quant, Heron Therapeutics' Cash from Investing Activities skyrocketed by 35197.97% in 2022 and then crashed by 53720.93% in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Cash from Investing Activities stood at -$24.3 million in 2021, then skyrocketed by 108.33% to $2.0 million in 2022, then crashed by 537.21% to -$8.8 million in 2023, then soared by 229.22% to $11.4 million in 2024, then grew by 3.85% to $11.9 million in 2025.
  • Its Cash from Investing Activities was $11.9 million in Q3 2025, compared to $7.3 million in Q2 2025 and $2.3 million in Q1 2025.